| ORIGINAL ARTICLE |
|
| Year : 2023 | Volume
: 22
| Issue : 1 | Page : 82-87 |
|
|
Outcome and safety of colistin usage in pediatric cancer patients with carbapenem-resistant enterobacteriaceae bacteremia at children cancer hospital Egypt
Nagla Adel1, Reham Khedr2, Mervat Elanany3, Hala F Zaki4, Hanafy Hafez2, Hanan El-Abhar4
1 Department of Pharmaceutical Services, Children's Cancer Hospital Egypt, Cairo, Egypt
2 Department of Pediatric Oncology, National Cancer Institute, Cairo University, Giza; Department of Pediatric Oncology, Children's Cancer Hospital Egypt, Cairo, Egypt
3 Department of Clinical Pathology, Cairo University, Giza; Department of Microbiology, Children's Cancer Hospital Egypt, Cairo, Egypt
4 Department of Pharmacology, Toxicology and Biochemistry Faculty of Pharmacy, Future University in Egypt, Giza, Egypt
Correspondence Address:
Reham Khedr
Department of Pediatric Oncology, National Cancer Institute, Cairo University, Cairo; Department of Pediatric Oncology, Children's Cancer Hospital Egypt, Cairo
Egypt
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/aam.aam_209_21
|
|
|
Background: Carbapenem resistant Enterobacteriacae (CRE) bloodstream infection (BSI) causes complicated infections, especially in immunocompromised patients. This study aimed to assess the renal toxicity and the efficacy of therapy with colistin in a cohort of pediatric cancer patients with BSIs due to CRE and sensitivity to colistin. Patients and Methods: This was an observational, prospective cohort study from May 2017 to October 2017 in Children's Cancer Hospital Egypt 57,357. All patients who had blood stream infections due to CRE receiving intravenous colistin were prospectively enrolled. We used a standardized case form to record patient characteristics, including age, sex, weight, underlying comorbidities, type of infection, causative organism, and antibiotic susceptibility testing. Daily doses, duration of colistin therapy, and co-administered antibiotics (aminoglycosides, vancomycin) were collected. Furthermore, clinical and microbiological responses to treatment were reported. The dosing schedule was based on a loading dose of 5 MU and a 5-MU twice-daily divided maintenance dose, titrated on renal function. Clinical cure, bacteriological clearance, and daily serum creatinine were recorded. Results: One hundred and forty-one Blood Stream infectious episodes mainly due to Klebsiella Species (pneumoniae and Oxytoca) (27%) and Escherichia coli (68%) were analyzed. All strains were susceptible to colistin with Minimum inhibitory concentration (MICs) of 0.19–1.5 mg/L. Patients were predominantly females (69%), with a mean age of 7 years. It was used as a combination therapy with carbapenems (69.2%) or aminoglycosides (80%). The median duration of treatment was 9 days (Range 1–50 days). Clinical and microbiological cure was observed in 110 cases (80%). Acute kidney injury developed during five treatment courses (4%) in which colistin was used in combination with amikacin. No renal replacement therapy was required and subsided within 7 days from colistin discontinuation. Conclusions: Our study showed that colistin had a high efficacy without significant renal toxicity in severe infections due to CRE Gram-negative bacteria.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
